Ning Ding
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ning Ding has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Shengsheng Zhang
Digestive Disease Center, Beijing Hospital of Traditional Chinese Medicine, Beijing 100010, China
2 shared publications - Dan Dou
Digestive Disease Center, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China
1 shared publication Danyan Li
Digestive Disease Center, Beijing Hospital of Traditional Chinese Medicine Capital Medical University Beijing China
1 shared publicationJiake Li
Clinical Medical College Beijing University of Chinese Medicine Beijing China
1 shared publication- Jixiang Liu
Graduate School , Beijing University of Chinese Medicine , No. 11 North 3rd Ring East Road Chaoyang, Beijing , 100029 , China , bucm.edu.cn
1 shared publication Jun Zhang
Clinical Medical College Beijing University of Chinese Medicine Beijing China
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Canadian Respiratory Journal
- Vol. 2026 (1) , 2846550
Influence of the COVID‐19 Pandemic on the Prevalence of Depression Among US Adults
Background: The prevalence of depressive symptoms increased significantly in the early stages of the COVID‐19 pandemic and remained elevated even as lockdown policies were eased. Therefore, a thorough evaluation of the pandemic’s long‐term effects on depressive disorders is critical. Methods: A repeated cross‐sectional study was conducted using data from the National Health Interview Survey collected before (2017–2018) and during the later stage of the COVID‐19 pandemic (August 2021−August 2023). χ 2 tests were conducted to compare the characteristics between nondepressed and depressed adults. Weighted multivariable logistic regression models were employed to estimate the associations between social and physical factors with depressive symptoms. Results: The prevalence of depressive symptoms in the later stages of the COVID‐19 pandemic (12.7%) was significantly higher than prepandemic levels (9.1%). Specifically, the incidence rates for mild, moderate, moderately severe, and severe depressive symptoms increased by 1.24‐fold, 1.44‐fold, 1.38‐fold, and 1.71‐fold, respectively, compared to prepandemic levels. Higher risk of developing depressive disorders persisted among those who were widowed/divorced/separated, never married, and with lower education or income. Prepandemic protective factors such as lower systemic inflammatory response index, no smoking or drinking, and no hypertension history became less effective. Males and females aged 20–40 exhibited the highest probability of developing depressive symptoms in the later stage of the pandemic. Limitations: The cross‐sectional design prevents inference of causality. Conclusions: The persistence of mental health disparities highlights the need for sustained efforts from the government, mental healthcare organizations, and healthcare providers to support vulnerable groups even beyond the pandemic.
- 1 January 2026
- Published by Wiley in Canadian Respiratory Journal
- Vol. 2026 (1) , 2846550
Open AccessInfluence of the COVID‐19 Pandemic on the Prevalence of Depression Among US Adults
Background: The prevalence of depressive symptoms increased significantly in the early stages of the COVID‐19 pandemic and remained elevated even as lockdown policies were eased. Therefore, a thorough evaluation of the pandemic’s long‐term effects on depressive disorders is critical. Methods: A repeated cross‐sectional study was conducted using data from the National Health Interview Survey collected before (2017–2018) and during the later stage of the COVID‐19 pandemic (August 2021−August 2023). χ 2 tests were conducted to compare the characteristics between nondepressed and depressed adults. Weighted multivariable logistic regression models were employed to estimate the associations between social and physical factors with depressive symptoms. Results: The prevalence of depressive symptoms in the later stages of the COVID‐19 pandemic (12.7%) was significantly higher than prepandemic levels (9.1%). Specifically, the incidence rates for mild, moderate, moderately severe, and severe depressive symptoms increased by 1.24‐fold, 1.44‐fold, 1.38‐fold, and 1.71‐fold, respectively, compared to prepandemic levels. Higher risk of developing depressive disorders persisted among those who were widowed/divorced/separated, never married, and with lower education or income. Prepandemic protective factors such as lower systemic inflammatory response index, no smoking or drinking, and no hypertension history became less effective. Males and females aged 20–40 exhibited the highest probability of developing depressive symptoms in the later stage of the pandemic. Limitations: The cross‐sectional design prevents inference of causality. Conclusions: The persistence of mental health disparities highlights the need for sustained efforts from the government, mental healthcare organizations, and healthcare providers to support vulnerable groups even beyond the pandemic.
- 25 October 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (12) , 2286-2296
The effect of T cell-related vaccines on inflammatory bowel disease: A systematic review and meta-analysis
- 25 October 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (12) , 2286-2296
The effect of T cell-related vaccines on inflammatory bowel disease: A systematic review and meta-analysis
- 30 November 2022
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 47 (12) , 1952-1965
Management of biologics in pregnant, lactating patients with inflammatory bowel disease and the impact on neonatal vaccination: A systematic review of clinical practice guidelines and consensus statements
- 30 November 2022
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 47 (12) , 1952-1965
Management of biologics in pregnant, lactating patients with inflammatory bowel disease and the impact on neonatal vaccination: A systematic review of clinical practice guidelines and consensus statements